Evidence map›Paper›PMID 42803943›Full record

ArticleCancer immunology research2026

ULK1-dependent autophagy initiation promotes MHC-I degradation and immune evasion in HPV-positive head and neck cancer.

Lexi Vu, Nicholas S Giacobbi, Mohamed I Khalil, Canchai Yang, William J Eckerman, Evelyn D Gomez Recinos, Johnathon D Garber, Abigail Z Bennett, Bryttan Adams, Hyomin Son and 10 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lexi VuMichigan State University East Lansing, MI United States.ORCID 0000-0001-9243-7469
Nicholas S GiacobbiMichigan State University East Lansing, MI United States.ORCID 0009-0009-2526-3687
Mohamed I KhalilMichigan State University East Lansing, MI United States.ORCID 0000-0002-8331-1490
Canchai YangMichigan State University East Lansing, MI United States.ORCID 0000-0002-0125-9298
William J EckermanMichigan State University East Lansing, MI United States.ORCID 0009-0008-6706-2982
Evelyn D Gomez RecinosMichigan State University East Lansing, MI United States.ORCID 0009-0007-6113-2145
Johnathon D GarberMichigan State University East Lansing, MI United States.ORCID 0009-0006-0659-5211
Abigail Z BennettMichigan State University East Lansing, MI United States.ORCID 0009-0006-1066-0397
Bryttan AdamsMichigan State University East Lansing, MI United States.ORCID 0009-0003-7586-2780
Hyomin SonMichigan State University East Lansing, MI United States.ORCID 0009-0007-2052-5591
Prerna ChahalMichigan State University East Lansing, MI United States.ORCID 0009-0004-4770-0853
Dara M VillaMichigan State University East Lansing, MI United States.ORCID 0009-0006-2141-3121
Tanisha SrivastavaMichigan State University East Lansing, MI United States.ORCID 0009-0004-7604-9449
Katie R MartinMichigan State University Grand Rapids, MI United States.ORCID 0000-0002-3689-4814
Craig C WelbonSanford Research Sioux Falls, South Dakota United States.ORCID 0000-0002-3134-0636
Caitlin S WilliamsonSanford Research Sioux Falls, South Dakota United States.ORCID 0000-0003-1335-9517
William C SpanosSanford Cancer Research Center Sioux Falls, South Dakota United States.ORCID 0000-0002-7975-1151
Jeffrey P MacKeiganMichigan State University Grand Rapids, MI United States.ORCID 0000-0002-0198-5679
Andrew J OliveMichigan State University East Lansing, MI United States.ORCID 0000-0003-3441-3113
Dohun PyeonMichigan State University East Lansing, MI United States.ORCID 0000-0003-1970-844X

Funding

Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancerR01DE029524 · NIDCR · MICHIGAN STATE UNIVERSITY · PI PYEON, DOHUN, SPANOS, WILLIAM CHARLES · 2020 to 2024
$3.2M
Regulators of IFN-gamma responses during Mycobacterium tuberculosis infectionR01AI165618 · NIAID · MICHIGAN STATE UNIVERSITY · PI Andrew Olive · 2022 to 2026
$2.6M
ULK Inhibition Rewires Tumor and Immune Cell MetabolismR01CA297993 · NCI · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI Russell Graham Jones, Jeffrey Paul MacKeigan · 2025 to 2026
$1.4M
Immune receptor degradation for immune evasion of head and neck cancerR01DE033797 · NIDCR · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI QING-SHENG MI, Dohun Pyeon · 2025 to 2026
$1.3M
Membrane Ubiquitin Ligase-Driven Immune Evasion in HPV+ Head and Neck CancerF31DE034281 · NIDCR · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI VU, LEXI · 2024 to 2025
$95k
NCI NIH HHS R01 CA297993NIAID NIH HHS R01 AI165618NIDCR NIH HHS F31 DE034281NIDCR NIH HHS R01 DE029524NIDCR NIH HHS R01 DE033797
6 · The paper itself

Abstract

Antigen presentation by major histocompatibility complex class I (MHC-I) is critical for tumor cell killing by CD8+ T cells. In human papillomavirus-positive head and neck cancer (HPV+ HNC), where MHC-I downregulation is frequent despite favorable immune cell infiltration, lower MHC-I levels are associated with poor responses to immune checkpoint inhibitor therapy. However, the mechanism of MHC-I degradation remains elusive. Genome-wide CRISPR screens in HPV+ HNC identified components of the ULK1 and PIK3C3 autophagy initiation complexes among top negative regulators of cell-surface MHC-I. In contrast, inhibiting post-initiation stages of autophagy did not restore cell-surface MHC-I, highlighting a critical role for autophagy initiation in regulation of MHC-I. Mechanistically, we showed that MHC-I is recruited from the ER to autophagosomes by the cargo receptor NDP52. Finally, inhibition of autophagy initiation suppressed HPV+ HNC tumor growth in vivo and enhanced the CD8+ T cell-mediated antitumor response. Our findings suggest that autophagic degradation of MARCHF8-ubiquitinated MHC-I is a key immune evasion mechanism in HPV+ HNC.

Identifiers

PMID42803943
PMCPMC13676309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.